CorMedix (CRMD) catalysts

Upcoming FDA decisions and readouts we track for CorMedix, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 24 Oct 2026

FreeBioList tracks 1 upcoming catalyst for CorMedix (CRMD, listed on Nasdaq). It concerns REZZAYO (rezafungin for injection) (Prophylaxis of invasive fungal disease).

First on the list: the PDUFA date for REZZAYO (rezafungin for injection) (Prophylaxis of invasive fungal disease), guided by the company to Q1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 24 Oct 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: CRMD
Next catalyst: Q1 2027
Type: PDUFA date
Listed options: Not yet checked

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
CorMedix CRMD · Nasdaq	REZZAYO (rezafungin for injection)	Prophylaxis of invasive fungal disease	Q1 2027 company guidance	PDUFA date	Verified	8-K exhibit 99.1 ↗	—
Notes — Filing states the FDA "has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027." The sNDA was submitted by partner Mundipharma. Source: 8-K exhibit 99.1, filed 19 Oct 2026 · verified 24 Oct 2026

Also due in Q1 2027

Pharming Group (PHAR)PDUFA date for Leniolisib (Joenja) lower doses, 30 Jan 2027
Arcutis Biotherapeutics (ARQT)PDUFA date for ZORYVE (roflumilast) cream 0.05%, 23 Feb 2027
Belite Bio (BLTE)PDUFA date for Tinlarebant, 12 Feb 2027
argenx SE (ARGX)PDUFA date for Efgartigimod (VYVGART / VYVGART Hytrulo), Feb 2027
Aquestive Therapeutics (AQST)PDUFA date for Anaphylm (dibutepinephrine) sublingual film, 16 Mar 2027
Intellia Therapeutics (NTLA)PDUFA date for Lonvoguran ziclumeran (lonvo-z), 10 Mar 2027